MedTrace Logo

Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial

NCT01896388 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-03-19

No results posted yet for this study

Summary

Accumulating evidence suggests a key role of the N-methyl-D-aspartate (NMDA) receptor in the pathophysiology of post-traumatic stress disorder (PTSD). Recent studies suggest that the NMDA receptor antagonist ifenprodil tartrate may be a potential therapeutic drug for PTSD. The purpose of this study is to confirm whether ifenprodil tartrate is effective in the treatment of adolescents PTSD patients. If ifenprodil tartrate is effective in these patients, this study contributes to the development of novel therapeutic drugs for PTSD.

Conditions

  • Posttraumatic Stress Disorders

Interventions

DRUG

Ifenprodil Tartrate

DRUG

Placebo

Sponsors & Collaborators

  • Chiba University

    lead OTHER

Principal Investigators

  • Masaomi Iyo, MD,PhD · Chairman, Department of Psychiatry, Chiba University Graduate School of Medicine

  • Nobuhisa Kanahara, MD,PhD · Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health

  • Tasuku Hashimoto, MD.PhD · Department of Psychiatry, Chiba University Graduate School of Medicine

  • Akihiro Shiina, MD,PhD · Department of Child Psychiatry, Chiba University Hospital

  • Tomihisa Niitsu, MD,PhD · Research Center for Child Mental Development, Chiba University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-21
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01896388 on ClinicalTrials.gov